Prescription Medicine for Women Over 40: A Complete Clinical Guide

Why 40 Is a Clinical Turning Point for Women

The fourth decade marks a genuine physiological inflection point. Ovarian reserve declines, estradiol output becomes erratic, and insulin sensitivity drops even in lean, active women. These changes do not arrive together or on schedule.

The Hormonal Cascade That Begins in Your 40s

Follicle-stimulating hormone (FSH) begins rising in the early 40s as granulosa cells produce less inhibin B. Estradiol levels fluctuate widely before declining, which explains why perimenopausal symptoms can appear years before the final menstrual period. A single low estradiol reading means little; the clinical picture matters more than any one value.

Progesterone production becomes irregular first, because ovulation itself becomes intermittent. This creates a window of relative estrogen dominance that may worsen migraines, breast tenderness, and mood symptoms before the eventual estrogen withdrawal of menopause.

Metabolic Changes That Deserve a Prescription Conversation

Visceral adiposity increases by roughly 10-15% in the five years surrounding menopause, independent of total caloric intake, according to data from the Study of Women's Health Across the Nation (SWAN) [1]. Fasting insulin rises, LDL particles become denser and more atherogenic, and resting energy expenditure falls. These are not inevitable consequences of aging. They are modifiable with targeted treatment.

Clinicians who treat only the hot flashes without addressing the metabolic shift are managing symptoms rather than disease trajectory.

Menopausal Hormone Therapy (MHT / HRT): Evidence and Options

Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause (GSM). The 2022 Menopause Society (NAMS) position statement states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." [2]

Estrogen: Formulations and Routes

Oral conjugated equine estrogen (CEE) and oral 17-beta estradiol are the two most studied formulations. Transdermal estradiol patches (0.025-0.1 mg/day) bypass first-pass hepatic metabolism, producing lower triglyceride elevation and, in several observational studies, lower venous thromboembolism (VTE) risk than oral routes [3].

The E3N cohort study (N=80,377 French women) found that transdermal estradiol combined with micronized progesterone carried no statistically significant increase in breast cancer risk over a median 8.1 years of follow-up, whereas synthetic progestins did carry elevated risk [4]. Route and progestogen type both matter.

Progestogen: Micronized vs. Synthetic

Women with an intact uterus require progestogen co-administration to prevent endometrial hyperplasia. Micronized progesterone (Prometrium 200 mg nightly for 12 days per cycle, or 100 mg continuous) is increasingly preferred over medroxyprogesterone acetate (MPA) based on the E3N data and favorable lipid profiles [4]. MPA was the progestogen used in the Women's Health Initiative (WHI), whose 2002 results triggered widespread (and partly overcorrected) abandonment of HRT [5].

Local Estrogen for Genitourinary Syndrome

Vaginal atrophy, dyspareunia, and recurrent UTIs respond well to low-dose local estrogen (vaginal estradiol cream 0.01%, estradiol vaginal tablets 10 mcg, or the estradiol vaginal ring). Systemic absorption from these doses is minimal. The FDA label was updated in 2023 to remove the black-box warning from ultra-low-dose vaginal estradiol products, reflecting the low systemic exposure [6].

Absolute Contraindications to Systemic HRT

• Unexplained vaginal bleeding
• History of estrogen-receptor-positive breast cancer
• Active or recent VTE or arterial thromboembolic event
• Known or suspected pregnancy
• Active liver disease with abnormal liver function

Testosterone Therapy in Women

Testosterone is not just a male hormone. Women produce it in the ovaries and adrenal glands, and circulating levels decline by roughly 50% between ages 20 and 45.

Who Benefits

The 2019 Global Consensus Position Statement on testosterone therapy for women concluded that there is "sufficient evidence to support testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD)" [7]. The evidence for other indications, including fatigue, cognitive fog, and mood, is promising but not yet definitive.

Dosing and Formulations

No FDA-approved female testosterone product exists in the United States as of 2025. Compounded transdermal testosterone cream (1-2 mg/day, targeting a serum total testosterone in the normal premenopausal range of 15-70 ng/dL) is the most common approach in telehealth and specialty practices. Testosterone pellets produce supraphysiologic levels in a significant minority of patients and are not recommended as first-line by most endocrine societies [8].

Monitoring

Check total testosterone and SHBG at baseline, then at 6 weeks after dose initiation, and every 6 months thereafter. Hematocrit and lipids should be assessed annually. Clitoromegaly, voice deepening, or acne suggests a dose reduction is needed.

GLP-1 Receptor Agonists for Weight and Metabolic Health

Weight gain after 40 is often attributed to willpower. The biology tells a different story. Estrogen loss reduces leptin sensitivity, impairs GLP-1 secretion, and shifts fat storage centrally. Prescription GLP-1 agonists address these mechanisms directly.

Semaglutide 2.4 mg (Wegovy)

STEP-1 (N=1,961) showed that once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) [9]. Women represented 75% of the STEP-1 cohort. In STEP-5 (N=304), the weight-loss effect was maintained at 104 weeks with continued treatment [10].

Semaglutide is FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or BMI >27 with at least one weight-related comorbidity.

Tirzepatide 15 mg (Zepbound)

The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg achieved 20.9% mean weight loss at 72 weeks, the largest reduction seen in any phase 3 weight-management trial to date [11]. As a dual GIP/GLP-1 agonist, tirzepatide appears to have additive effects on satiety and energy expenditure beyond GLP-1 agonism alone.

Who Should Consider a GLP-1 Agonist

Women over 40 with BMI >27 plus at least one of the following are reasonable candidates: prediabetes or type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or ASCVD. PCOS is an emerging indication with small but consistent trial data showing improvements in androgen levels and cycle regularity alongside weight loss [12].

Contraindications include personal or family history of medullary thyroid carcinoma or MEN2, active pancreatitis, and pregnancy.

Thyroid Disorders: Underdiagnosed and Undertreated

Hypothyroidism affects 5-10% of women and peaks in the 40-60 age range. Subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal free T4) affects an additional 10% [13].

When to Treat

The American Thyroid Association (ATA) 2014 guidelines recommend treatment for overt hypothyroidism (TSH above upper normal, low free T4) in all patients. For subclinical hypothyroidism, treatment is generally recommended when TSH exceeds 10 mIU/L, when symptoms are present, or when the patient is planning pregnancy [13].

Levothyroxine (L-T4) monotherapy is first-line. Starting dose is typically 1.6 mcg/kg/day, titrated to a TSH target of 0.5-2.5 mIU/L for most women under 65. Liothyronine (T3) add-on therapy is occasionally used in patients with persistent symptoms on adequate T4 monotherapy, but evidence for routine combination treatment is mixed [14].

Thyroid and Perimenopause: Overlapping Symptom Sets

Hot flashes, fatigue, weight gain, brain fog, and mood changes are common to both perimenopause and hypothyroidism. Checking TSH before attributing all symptoms to estrogen deficiency prevents missed diagnoses. A single TSH drawn in the morning is an adequate initial screen.

Mental Health Prescriptions: Depression, Anxiety, and Sleep

Perimenopause is a biologically sensitive period for mood disorders. The risk of a first depressive episode roughly doubles during the menopausal transition, even in women with no prior psychiatric history, based on data from the Penn Ovarian Aging Study [15].

SSRIs and SNRIs

SSRIs (escitalopram, sertraline) and SNRIs (venlafaxine, desvenlafaxine) are first-line for perimenopausal depression. Desvenlafaxine 100 mg/day was shown in a randomized controlled trial (N=567) to reduce vasomotor symptom frequency by 62% versus 38% placebo at 12 weeks, making it a dual-purpose option for women who cannot or prefer not to use estrogen [16].

Non-Hormonal Hot Flash Treatments

Fezolinetant (Veozah), approved by the FDA in May 2023, is the first neurokinin 3 receptor antagonist approved specifically for vasomotor symptoms. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg daily reduced moderate-to-severe hot flash frequency by 60% at week 4 and 65% at week 12 [17]. It carries a boxed warning for hepatotoxicity, requiring liver function monitoring at baseline, 3 months, and 6 months.

Sleep

Zolpidem, eszopiclone, and low-dose doxepin (3-6 mg) are FDA-approved for insomnia. In perimenopausal women, treating the underlying vasomotor symptoms often resolves sleep disruption without a separate hypnotic. Reserve dedicated sleep prescriptions for women whose insomnia persists after adequate hot flash management.

Bone Health: Preventing Fractures Before They Happen

Women lose up to 20% of their bone mineral density (BMD) in the 5-7 years immediately following menopause [18]. Fracture risk climbs steeply after age 50, and a hip fracture carries a 20-30% one-year mortality rate in older women.

Screening

The U.S. Preventive Services Task Force (USPSTF) recommends dual-energy X-ray absorptiometry (DEXA) screening for all women aged 65 and older and for younger postmenopausal women whose FRAX 10-year fracture risk equals or exceeds that of a 65-year-old white woman [19].

Prescription Options

Alendronate (70 mg weekly) and risedronate (35 mg weekly) are oral bisphosphonates with the most long-term safety data. Zoledronic acid (5 mg IV annually) is preferred for patients with GI intolerance or absorption concerns. Denosumab (Prolia, 60 mg subcutaneously every 6 months) is second-line and requires continuity of treatment because discontinuation can cause rebound vertebral fractures [20].

MHT also preserves BMD, and in women under 60 who are already receiving estrogen for vasomotor symptoms, additional osteoporosis medication is often unnecessary.

Cardiovascular Risk: Statins and Aspirin After 40

ASCVD becomes the leading cause of death in women after menopause. Pre-menopausal estrogen has cardioprotective effects; their withdrawal accelerates atherosclerosis.

Statins

The ACC/AHA 2019 cardiovascular risk guidelines recommend statin therapy when the 10-year ASCVD risk exceeds 7.5% and the clinician-patient risk discussion supports treatment [21]. Women are systematically under-prescribed statins compared with men at equivalent risk levels.

High-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) reduce LDL by 50% or more and cardiovascular events by roughly 25% in high-risk populations. For primary prevention in women aged 40-75 with elevated risk, the benefit-risk balance clearly favors treatment.

Aspirin

The 2022 USPSTF guideline no longer recommends aspirin for primary prevention in adults aged 60 and older due to bleeding risk. In women aged 40-59 with a 10-year ASCVD risk of 10% or greater, low-dose aspirin (81 mg daily) may be considered after a shared decision-making discussion [22].

Comparison Table: Prescription Options for Women Over 40

| Treatment | Primary Indication | Evidence Grade | Key Risk | |---|---|---|---| | Oral estradiol (1-2 mg/day) | Vasomotor symptoms | Grade A | VTE, slight breast cancer risk with long-term use | | Transdermal estradiol (0.05 mg/day patch) | Vasomotor symptoms, BMD | Grade A | Lower VTE risk vs. Oral | | Micronized progesterone (100-200 mg/day) | Endometrial protection | Grade A | Sedation, rare idiosyncratic hepatotoxicity | | Low-dose vaginal estradiol (10 mcg tablet) | GSM, recurrent UTI | Grade A | Minimal systemic effect | | Testosterone (compounded, 1-2 mg/day transdermal) | HSDD | Grade B | Acne, androgenic side effects at high doses | | Semaglutide 2.4 mg weekly | Weight management | Grade A | Nausea, rare pancreatitis, MTC history | | Tirzepatide 15 mg weekly | Weight management | Grade A | Same as semaglutide class | | Levothyroxine (weight-based dosing) | Hypothyroidism | Grade A | Over-treatment causing AF and bone loss | | Fezolinetant 45 mg/day | Vasomotor symptoms (non-hormonal) | Grade A | Hepatotoxicity | | Alendronate 70 mg weekly | Osteoporosis prevention/treatment | Grade A | Osteonecrosis of jaw (rare), atypical femur fracture | | Atorvastatin 40-80 mg/day | ASCVD risk reduction | Grade A | Myopathy, transaminase elevation | | Desvenlafaxine 100 mg/day | Depression, vasomotor symptoms | Grade A | Discontinuation syndrome, hypertension |

Monitoring Protocol: Baseline and Follow-Up Labs

Before initiating any hormonal prescription, the HealthRX clinical team orders the following baseline panel. This is not a universal standard, but reflects the protocol developed from our clinical experience with telehealth patients:

Baseline (all patients over 40 considering hormonal therapy):

• TSH (thyroid function screen)
• Estradiol (day 2-3 of cycle if premenopausal, any time if postmenopausal)
• Total and free testosterone, SHBG
• FSH (to assess ovarian reserve in perimenopause)
• CBC, CMP (hepatic and renal baseline)
• Fasting lipid panel
• Hemoglobin A1c and fasting glucose
• Blood pressure measurement

At 3 months after initiation:

• Symptom reassessment using validated tools (MRS or MENQOL)
• Repeat relevant hormone levels (estradiol on transdermal estrogen, testosterone on TRT)
• Blood pressure, weight

At 12 months:

• Full repeat of baseline labs
• DEXA if age 65+ or FRAX-indicated
• Mammogram (annual per ACR guidelines for average-risk women aged 40+)
• Pap smear / cervical screening per ASCCP guidelines

Who Should Not Self-Prescribe or Use Over-the-Counter Hormones

Bioidentical hormone supplements sold without a prescription are not regulated for potency or purity. Progesterone creams achieve serum levels that are roughly 10-fold lower than oral micronized progesterone and are insufficient for endometrial protection [23]. Women using unregulated compounded hormones without physician oversight are taking on uterine cancer risk without knowing it.

Any woman who has had unexplained vaginal bleeding in the last 12 months must be evaluated with endometrial sampling before starting or resuming estrogen therapy. No exceptions.